Black Diamond Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Black Diamond Therapeutics, a precision oncology company, announced that its CEO, David M. Epstein, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 1:30 PM ET. The presentation will cover the company's advancements in tumor-agnostic therapies, targeting undrugged mutations in cancers. Investors can access a live webcast and replay on the company’s website for three weeks. Black Diamond's MAP platform allows for the development of tailored therapies based on genetic data.
- None.
- None.
CAMBRIDGE, Mass. and NEW YORK, May 27, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the Jefferies Virtual Healthcare Conference. The presentation will take place on Wednesday, June 3, 2020, at 1:30 PM ET.
A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.
About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts:
For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com
For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com
FAQ
What is the date and time of Black Diamond Therapeutics' presentation at the Jefferies Virtual Healthcare Conference?
How can I access the presentation by Black Diamond Therapeutics?
What is the main focus of Black Diamond Therapeutics at the Jefferies Conference?
When will the replay of the presentation by Black Diamond Therapeutics be available?